help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ROSSMAN, M. D.
Right arrow Articles by MONOS, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ROSSMAN, M. D.
Right arrow Articles by MONOS, D.

Am. J. Respir. Crit. Care Med., Volume 165, Number 6, March 2002, 788-794

Human Leukocyte Antigen Class II Amino Acid Epitopes
Susceptibility and Progression Markers for Beryllium Hypersensitivity

MILTON D. ROSSMAN, JOSE STUBBS, CHUNG WHA LEE, ELIAS ARGYRIS, ELENI MAGIRA, and DIMITRI MONOS

Departments of Medicine and Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and Laboratory of Human Biology and Genetics, Democritus University of Thrace, School of Medicine, Alexandroupolis, Greece

Chronic beryllium disease (CBD) is a hypersensitivity granulomatosis characterized by beryllium hypersensitivity (BH) and mediated by CD4+ T cells. However, all individuals with BH may not develop CBD. To examine the role of the three different human leukocyte antigen (HLA) Class II isotypes in BH with (CBD) and without clinical disease (BHWCD), we performed DNA-based typing of HLA-DPB1, HLA-DQB1, and HLA-DRB1 loci on 55 subjects with BH (25 with established CBD and 30 with BHWCD), and compared this with the results for 82 beryllium-exposed workers with no evidence of BH. The allele distribution was utilized to identify candidate amino acid epitopes that differed between the study groups. HLA-DPB1-E69 was the most important marker for BH, and did not differentiate BHWCD from CBD. A significant association with CBD was observed with HLA-DQB1-G86 (pcorr < 0.04), and HLA-DRB1-S11 was significantly increased in CBD as compared with BHWCD (p < 0.03). These observations suggest that HLA-DPB1-E69 is a marker for susceptibility to BH and not just a progression marker for CBD. In addition, HLA amino acid epitopes on HLA-DRB1 and -DQB1, in concert with or independently of HLA-DPB1-E69, may be associated with progression to CBD.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
D. G. Mack, A. M. Lanham, B. E. Palmer, L. A. Maier, and A. P. Fontenot
CD27 Expression on CD4+ T Cells Differentiates Effector from Regulatory T Cell Subsets in the Lung
J. Immunol., June 1, 2009; 182(11): 7317 - 7324.
[Abstract] [Full Text] [PDF]

Home page
 J R Soc InterfaceHome page
J. A Snyder, E. Demchuk, E. C McCanlies, C. R Schuler, K. Kreiss, M. E Andrew, B. L Frye, J. S Ensey, M. L Stanton, and A. Weston
Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease
J R Soc Interface, July 6, 2008; 5(24): 749 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Occup. Environ. Med.Home page
D C Christiani, A J Mehta, and C-L Yu
Genetic susceptibility to occupational exposures
Occup. Environ. Med., June 1, 2008; 65(6): 430 - 436.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. A. Maier, J. W. Martyny, J. Liang, and M. D. Rossman
Recent Chronic Beryllium Disease in Residents Surrounding a Beryllium Facility
Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1012 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. C. Jonth, L. Silveira, T. E. Fingerlin, H. Sato, J. C. Luby, K. I. Welsh, C. S. Rose, L. S. Newman, R. M. du Bois, L. A. Maier, et al.
TGF-beta1 Variants in Chronic Beryllium Disease and Sarcoidosis
J. Immunol., September 15, 2007; 179(6): 4255 - 4262.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. P. Fontenot, T. S. Keizer, M. McCleskey, D. G. Mack, R. Meza-Romero, J. Huan, D. M. Edwards, Y. K. Chou, A. A. Vandenbark, B. Scott, et al.
Recombinant HLA-DP2 Binds Beryllium and Tolerizes Beryllium-Specific Pathogenic CD4+ T Cells
J. Immunol., September 15, 2006; 177(6): 3874 - 3883.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Muller-Quernheim, K. I. Gaede, E. Fireman, and G. Zissel
Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients
Eur. Respir. J., June 1, 2006; 27(6): 1190 - 1195.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. R. Bill, D. G. Mack, M. T. Falta, L. A. Maier, A. K. Sullivan, F. G. Joslin, A. K. Martin, B. M. Freed, B. L. Kotzin, and A. P. Fontenot
Beryllium Presentation to CD4+ T Cells Is Dependent on a Single Amino Acid Residue of the MHC Class II {beta}-Chain
J. Immunol., November 15, 2005; 175(10): 7029 - 7037.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. S. Newman, M. M. Mroz, R. Balkissoon, and L. A. Maier
Beryllium Sensitization Progresses to Chronic Beryllium Disease: A Longitudinal Study of Disease Risk
Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 54 - 60.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. Verougstraete, A. Mallants, J.-P. Buchet, B. Swennen, and D. Lison
Lung Function Changes in Workers Exposed to Cobalt Compounds: A 13-Year Follow-up
Am. J. Respir. Crit. Care Med., July 15, 2004; 170(2): 162 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. T. Sawyer, C. E. Parsons, A. P. Fontenot, L. A. Maier, M. M. Gillespie, E. B. Gottschall, L. Silveira, and L. S. Newman
Beryllium-Induced Tumor Necrosis Factor-{alpha} Production by CD4+ T Cells Is Mediated by HLA-DP
Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 122 - 130.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. A. Maier, D. S. McGrath, H. Sato, P. Lympany, K. Welsh, R. du Bois, L. Silveira, A. P. Fontenot, R. T. Sawyer, E. Wilcox, et al.
Influence of MHC CLASS II in Susceptibility to Beryllium Sensitization and Chronic Beryllium Disease
J. Immunol., December 15, 2003; 171(12): 6910 - 6918.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
B. P. Barna, D. A. Culver, B. Yen-Lieberman, R. A. Dweik, and M. J. Thomassen
Clinical Application of Beryllium Lymphocyte Proliferation Testing
Clin. Vaccine Immunol., November 1, 2003; 10(6): 990 - 994.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. C. Iannuzzi, M. J. Maliarik, L. M. Poisson, and B. A. Rybicki
Sarcoidosis Susceptibility and Resistance HLA-DQB1 Alleles in African Americans
Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1225 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. E. Magira, M. Papaioakim, I. Nachamkin, A. K. Asbury, C. Y. Li, T. W. Ho, J. W. Griffin, G. M. McKhann, and D. S. Monos
Differential Distribution of HLA-DQ{beta}/DR{beta} Epitopes in the Two Forms of Guillain-Barre Syndrome, Acute Motor Axonal Neuropathy and Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Identification of DQ{beta} Epitopes Associated with Susceptibility to and Protection from AIDP
J. Immunol., March 15, 2003; 170(6): 3074 - 3080.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
E. C. McCanlies, K. Kreiss, M. Andrew, and A. Weston
HLA-DPB1 and Chronic Beryllium Disease: A HuGE Review
Am. J. Epidemiol., March 1, 2003; 157(5): 388 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Tuberculosis, Lung Infections, Interstitial Lung Disease, and Journalology in AJRCCM 2002
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 345 - 355.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society 		  ATS 2008 State of the Art Course